PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an Ernst & Young LLP (EY US) Entrepreneur Of The Year® 2024 New Jersey Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies.
Mr. Lalwani was selected by an independent judging panel made up of previous award winners, leading CEOs, and other business leaders. Candidates were evaluated based on their ability to create long-term value through entrepreneurial spirit, commitment to their purpose, and the demonstration of growth and substantial impact, among other key indicators.
Nikhil Lalwani, President and CEO of ANI, stated, “I am deeply humbled and honored to receive this prestigious award on behalf of the entire ANI Pharmaceuticals team. We remain steadfastly committed to our purpose: Serving Patients, Improving Lives. In parallel, we have achieved strong financial results, increasing our Enterprise Value approximately 2.8X since September 2020, when I joined as CEO. Each ANI team member and our Board has played an important role in driving our success. I share this honor with them and our customers, suppliers, partners, and shareholders whose support we count on and are so grateful for.”
As a New Jersey award winner, Mr. Lalwani is now eligible for consideration for the Entrepreneur Of The Year 2024 National Awards and for the World Entrepreneur Of The Year® Award in June 2025.
The Entrepreneur Of The Year program has recognized the leadership of entrepreneurs such as:
Entrepreneur Of the Year recognizes many different types of business leaders for their ingenuity, courage, and entrepreneurial spirit. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to fortify it for the future.
In addition to Entrepreneur Of The Year, EY US supports other entrepreneurs through the EY Entrepreneurial Winning Women™ (Winning Women) program and the EY Entrepreneurs Access Network (EAN) to help connect women founders and Black and Hispanic/Latino entrepreneurs, respectively, with the resources, network and access needed to unlock their full potential.
Sponsors
Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting sponsors PNC Bank, Cresa, Marsh USA, SAP, and the Ewing Marion Kauffman Foundation. In New Jersey, sponsors also include DLA Piper and Empire Valuation Consultants.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin® Gel, strengthening its Generics business with enhanced research and development capabilities, delivering innovation in Established Brands, and leveraging its U.S. based manufacturing footprint. For more information, please visit our website www.anipharmaceuticals.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Faith Pomeroy-Ward
T: 817-807-8044
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$53.35 |
| Daily Change: | -0.91 -1.68 |
| Daily Volume: | 948,376 |
| Market Cap: | US$1.120B |
November 08, 2024 November 04, 2024 October 24, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
